¼¼°èÀÇ µðÁöÅÐ À¯Àüü ½ÃÀå
Digital Genomes
»óǰÄÚµå : 1739337
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 184 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,496,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,489,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

µðÁöÅÐ À¯Àüü ¼¼°è ½ÃÀåÀº 2030³â±îÁö 728¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 337¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â µðÁöÅÐ À¯Àüü ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 13.7%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 728¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ½ÃÄö½Ì ¹× ºÐ¼®±â ±â±â´Â CAGR 16.1%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á±îÁö 318¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. DNA/RNA ¾î¼¼ÀÌ Å°Æ® ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ CAGR·Î 11.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 89¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 12.8%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ µðÁöÅÐ À¯Àüü ½ÃÀåÀº 2024³â¿¡ 89¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 112¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 12.8%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 13.0%¿Í 11.5%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 9.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è µðÁöÅÐ À¯Àüü ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

Á¤¹ÐÀÇ·á´Â µðÁöÅÐ À¯ÀüüÀÇ ½Ã´ë·Î?

µðÁöÅÐ À¯Àüü´Â °³ÀÎÀÇ ¿ÏÀüÇÑ À¯ÀüÄڵ带 °¡»óÀ¸·Î Ç¥ÇöÇϰí ÷´Ü ÄÄÇ»ÆÃ ½Ã½ºÅÛÀ» »ç¿ëÇÏ¿© ÀúÀå ¹× ºÐ¼®ÇÑ °ÍÀ¸·Î, ¸ÂÃãÇü ÀÇ·á, ÀǾàǰ °³¹ß, Áúº´ ¿¹¹æÀÇ ÆÇµµ¸¦ ¹Ù²Ù°í ÀÖ½À´Ï´Ù. µðÁöÅÐ À¯Àüü ¼¼°è ½ÃÀåÀº Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®±â(NGS), AI¸¦ Ȱ¿ëÇÑ ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º, Ŭ¶ó¿ìµå ±â¹Ý µ¥ÀÌÅÍ ½ºÅ丮ÁöÀÇ À¶ÇÕ¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖÀ¸¸ç, ½Å¼ÓÇϰí È®Àå °¡´ÉÇÏ¸ç ºñ¿ë È¿À²ÀûÀÎ À¯ÀüÀÚ ºÐ¼®ÀÌ °¡´ÉÇØÁ³½À´Ï´Ù.

°áÁ¤ÀûÀÎ Æ®·»µå´Â »çÀÏ·ÎÈ­µÈ À¯ÀüÀÚ °Ë»ç¿¡¼­ ¿ø½Ã DNA µ¥ÀÌÅÍ, Ç¥ÇöÇü ¿¬°á, °Ç°­ ±â·Ï, ½Ç½Ã°£ ¸ð´ÏÅ͸µÀ» ÅëÇÕµÈ ÀÎÅÍÆäÀ̽º·Î ÅëÇÕÇÏ´Â ÅëÇÕ µðÁöÅÐ À¯Àüü Ç÷§ÆûÀ¸·Î ÀüȯÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Ç÷§ÆûÀº Á¾¾çÇÐ, Èñ±ÍÁúȯ Áø´Ü, ¾à¸®À¯ÀüüÇÐ, Áý´ÜÀ¯ÀüüÇÐ ºÐ¾ß¿¡¼­ Ȱ¿ëÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¹Ì±¹, ¿µ±¹, Áß±¹ µîÀÇ ±¹°¡µéÀº ±¹°¡ Â÷¿øÀÇ À¯Àüü ¸ÅÇÎ ÇÁ·ÎÁ§Æ®¿¡ ÅõÀÚÇϰí ÀÖÀ¸¸ç, µ¥ÀÌÅÍ·®ÀÌ Ç³ºÎÇϰí Ŭ¶ó¿ìµå¿¡¼­ ¾ÈÀüÇÑ µðÁöÅÐ À¯Àüü ÀÎÇÁ¶óÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

±â¼ú À¶ÇÕÀº À¯ÀüüÀÇ °¡´É¼ºÀ» ¾î¶»°Ô ¿­¾îÁÙ±î?

AI¿Í ¸Ó½Å·¯´× ¾Ë°í¸®ÁòÀº µðÁöÅÐ À¯Àüü Çõ¸íÀÇ ÇÙ½ÉÀ¸·Î, ½Å¼ÓÇÑ º¯Á¾ °ËÃâ, À§Çè ¸ðµ¨¸µ, Ä¡·á Ç¥Àû ½Äº°À» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ÀÓ»óÀǰ¡ º¹ÀâÇÑ À¯Àüü µ¥ÀÌÅͼ¼Æ®¸¦ ÇØ¼®Çϰí ÃÖÀûÀÇ Ä¡·á¹ýÀ» ã¾Æ³»´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿þ¾î·¯ºí¿¡ ÅëÇÕµÈ °Ç°­ µ¥ÀÌÅ͸¦ ÅëÇØ °³ÀÎÀÇ À¯Àüü ÇÁ·ÎÆÄÀÏÀ» ½Ç½Ã°£À¸·Î ¾÷µ¥ÀÌÆ®ÇÒ ¼ö ÀÖ°Ô µÇ¾úÀ¸¸ç, ƯÈ÷ Á¾´ÜÀû °Ç°­ Á¶»ç¿¡¼­ ´õ¿í ±×·¯ÇÕ´Ï´Ù.

ÀúÀå ¹× ¾Ïȣȭ ±â¼úÀÇ ¹ßÀüÀ¸·Î À¯ÀüÀÚ µ¥ÀÌÅÍÀÇ ¾ÈÀüÇÑ °øÀ¯µµ °¡´ÉÇØÁ³½À´Ï´Ù. ÅëÇÕ µ¥ÀÌÅÍ ¸ðµ¨°ú ºí·ÏüÀÎÀº GDPR¿¡ ±â¹ÝÇÑ EU³ª HIPAA¿¡ ±â¹ÝÇÑ ¹Ì±¹°ú °°Àº ±ÔÁ¦ ȯ°æ¿¡¼­ Áß¿äÇÑ °ü½É»çÀΠȯÀÚÀÇ ÇÁ¶óÀ̹ö½Ã¸¦ Ä§ÇØÇÏÁö ¾Ê°í °Ô³ð µ¥ÀÌÅÍ¿¡ ´ëÇÑ ºÐ»êÈ­µÈ Á¢±ÙÀ» °¡´ÉÇÏ°Ô Çϱâ À§ÇØ °í·ÁµÇ°í ÀÖ½À´Ï´Ù.

¼ö¿ä°¡ °¡¼ÓÈ­µÇ°í ÀÖ´Â ½ÃÀå°ú ÃÖÁ¾»ç¿ëÀÚ´Â?

µðÁöÅÐ À¯Àüü ½ÃÀåÀº ºÏ¹Ì¿Í À¯·´¿¡¼­ ºü¸£°Ô ¼ºÀåÇϰí ÀÖÀ¸¸ç, ¾Æ½Ã¾ÆÅÂÆò¾çÀº Á¤ºÎ Áö¿ø À¯Àüü ½ÃÄö½Ì ÇÁ·Î±×·¥°ú »ý¸í°øÇÐ »ýŰè È®´ë·Î ÀÎÇØ Àü·«Àû ¼ºÀåÀÇ ÃÖÀü¼±À¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ÃÖÁ¾»ç¿ëÀÚ¿¡´Â Çмú ¿¬±¸±â°ü, º´¿ø, ¹ÙÀÌ¿À Á¦¾à»ç, ¼ÒºñÀÚ Á÷Á¢ ÆÇ¸Å(DTC) À¯ÀüÀÚ °Ë»ç Á¦°ø¾÷ü, ÀÇ·á º¸Çè»ç µîÀÌ Æ÷ÇԵ˴ϴÙ.

¿µ±¹ÀÇ 100,000 À¯Àüü ÇÁ·ÎÁ§Æ®³ª NIHÀÇ All of Us ¿¬±¸ ÇÁ·Î±×·¥°ú °°Àº Àα¸ °Ç°­ ÀÌ´Ï¼ÅÆ¼ºê°¡ ÁÖ¿ä ¼ºÀå Ã˸ÅÁ¦ÀÎ ¹Ý¸é, ºñ»óÀå À¯ÀüÀÚ °Ë»ç ȸ»çµéÀº ¼ÒºñÀÚ ´ë»ó À¯Àüü ´ë½Ãº¸µå¸¦ °³¹ßÇÏ¿© À¯ÀüÀû À§Çè°ú »ýȰ½À°ü ¹× À£ºù °³ÀÔÀ» ¿¬°áÇϰí ÀÖ½À´Ï´Ù. À¯ÀüÀû À§Çè°ú »ýȰ½À°ü ¹× À£ºù °³ÀÔÀ» ¿¬°áÇϰí ÀÖ½À´Ï´Ù.

µðÁöÅÐ À¯Àüü ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº?

µðÁöÅÐ À¯Àüü ½ÃÀåÀÇ ¼ºÀåÀº À¯Àüü °úÇÐ, AI ºÐ¼®, Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ¼ö¿äÀÇ ÇÕ·ù·Î ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ÀüÀå À¯Àüü ¿°±â¼­¿­ÀÇ °¡°ÝÀÌ »ó½ÂÇϰí Ŭ¶ó¿ìµå ÄÄÇ»ÆÃ¿¡ ´ëÇÑ Á¢±ÙÀÌ ¿ëÀÌÇØÁö¸é¼­ µðÁöÅÐ À¯Àüü Ç÷§ÆûÀ» äÅÃÇÏ´Â ÀÇ·á±â°üÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÇコÄÉ¾î ½Ã½ºÅÛÀº ƯÈ÷ Á¾¾çÇÐ, ½ÉÀåÇÐ, ½Å°æÇÐ ºÐ¾ß¿¡¼­ À§Çè °èÃþÈ­ ¹× Á¶±â °³ÀÔ¿¡ ÀÖ¾î À¯ÀüüÇÐÀÇ °¡Ä¡¸¦ ÀνÄÇϰí ÀÖ½À´Ï´Ù. Á¦¾à»çµéÀº µðÁöÅÐ À¯Àüü µ¥ÀÌÅͼ¼Æ®¸¦ Ȱ¿ëÇÏ¿© »õ·Î¿î ¾à¹° Ÿ°ÙÀ» ½Äº°Çϰí, À¯ÀüÀÚ ¹ÝÀÀ¼º¿¡ µû¶ó ÀÓ»ó½ÃÇè Âü°¡ÀÚ¸¦ °èÃþÈ­Çϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ¸íȮȭ¿Í µ¥ÀÌÅÍ °øÀ¯¿¡ ´ëÇÑ ¼¼°è Çù·ÂÀº µðÁöÅÐ À¯Àüü¸¦ ÁÖ·ù ÀÇÇп¡ ÅëÇÕÇÏ´Â °ÍÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç°(½ÃÄö½Ì ¹× ºÐ¼®±â ±â±â, DNA/RNA ¾î¼¼ÀÌ Å°Æ®, ½ÃÄö½Ì Ĩ, ½ÃÄö½Ì ¹× ºÐ¼® ¼ÒÇÁÆ®¿þ¾î, »ùÇà Á¶Á¦ ±â±â), ¿ëµµ(ÀÓ»ó, ¹ýÀÇÇÐ, Drug Discovery & Development, ±âŸ ¿ëµµ), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø, Áø´Ü ¼¾ÅÍ ¹× ¹ýÀÇÇÐ ¿¬±¸¼Ò, ¿¬±¸°³¹ß, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê(ÃÑ 44°³»ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¸ÅÃâ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù : Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù : ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м®:

¹Ì±¹ <> Áß±¹ <> ¸ß½ÃÄÚ <> ij³ª´Ù <> EU <> ÀϺ» <> Àεµ <> ±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ® : Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ® ±×·ìÀ» Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤À» Àû¿ëÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Digital Genomes Market to Reach US$72.8 Billion by 2030

The global market for Digital Genomes estimated at US$33.7 Billion in the year 2024, is expected to reach US$72.8 Billion by 2030, growing at a CAGR of 13.7% over the analysis period 2024-2030. Sequencing & Analyzer Instruments, one of the segments analyzed in the report, is expected to record a 16.1% CAGR and reach US$31.8 Billion by the end of the analysis period. Growth in the DNA / RNA Analysis Kits segment is estimated at 11.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$8.9 Billion While China is Forecast to Grow at 12.8% CAGR

The Digital Genomes market in the U.S. is estimated at US$8.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$11.2 Billion by the year 2030 trailing a CAGR of 12.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.0% and 11.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.8% CAGR.

Global Digital Genomes Market - Key Trends & Drivers Summarized

Is Precision Health Entering the Age of the Digital Genome?

Digital genomes-virtual representations of an individual’s complete genetic code stored and analyzed using advanced computing systems-are transforming the landscape of personalized medicine, drug development, and disease prevention. The global market for digital genomes is being driven by the convergence of next-generation sequencing (NGS), AI-enabled bioinformatics, and cloud-based data storage, enabling rapid, scalable, and cost-effective genetic analysis.

A defining trend is the shift from siloed genetic testing to integrated digital genome platforms, which consolidate raw DNA data, phenotype linkage, health records, and real-time monitoring into unified interfaces. These platforms are finding increasing use in oncology, rare disease diagnostics, pharmacogenomics, and population genomics initiatives. Countries such as the U.S., U.K., and China are investing in national-scale genome mapping projects, boosting the adoption of data-rich, cloud-secure digital genome infrastructure.

How Are Technological Convergences Unlocking Genomic Potential?

AI and machine learning algorithms are central to the digital genome revolution, facilitating rapid variant detection, risk modeling, and therapeutic target identification. These technologies are helping clinicians interpret complex genomic datasets and match them with optimal treatments-ushering in an era of predictive and preventive medicine. Moreover, real-time updates to individual genome profiles via wearable-integrated health data are becoming possible, especially in longitudinal health studies.

Advancements in storage and encryption technologies are also making secure sharing of genetic data feasible. Federated data models and blockchain are being explored to allow decentralized access to genomic data without compromising patient privacy, a key concern in regulated environments like the EU under GDPR or the U.S. under HIPAA.

Where Is Demand Accelerating and Who Are the End-Users?

The digital genome market is expanding rapidly in North America and Europe, with Asia-Pacific emerging as a strategic growth frontier due to government-backed genome sequencing programs and expanding biotech ecosystems. End-users include academic research institutions, hospitals, biopharmaceutical companies, direct-to-consumer (DTC) genetic testing providers, and health insurers.

Population health initiatives-such as the UK's 100,000 Genomes Project or the NIH's All of Us research program-are key growth catalysts, while private genetic testing companies are deploying consumer-facing genome dashboards to connect genetic risk with lifestyle and wellness interventions.

What’s Driving Growth in the Digital Genomes Market?

The growth in the digital genomes market is driven by a confluence of genomic science, AI analytics, and demand for precision medicine. Rising affordability of whole genome sequencing, along with increased accessibility to cloud computing, is enabling more institutions to adopt digital genome platforms.

Healthcare systems are recognizing the value of genomics in risk stratification and early intervention, particularly in oncology, cardiology, and neurology. Pharmaceutical firms are using digital genome datasets to identify novel drug targets and stratify trial participants based on genetic responsiveness. Regulatory clarity and global collaborations on data sharing are further fueling the integration of digital genomes into mainstream medicine.

SCOPE OF STUDY:

The report analyzes the Digital Genomes market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Sequencing & Analyzer Instruments, DNA / RNA Analysis Kits, Sequencing Chips, Sequencing & Analysis Software, Sample Preparation Instruments); Application (Clinical, Forensics, Drug Discovery & Development, Other Applications); End-User (Hospitals, Diagnostic Centers & Forensic Labs, Research Institutes, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â